Roche and Zealand Pharma ink a $5.3 billion deal to co-develop and co-commercialize an obesity drug, positioning Zealand alongside major weight-loss companies.
Roche and Zealand Pharma ink a $5.3 billion deal to co-develop and co-commercialize an obesity drug, positioning Zealand alongside major weight-loss companies.